MADISON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (Imbed) announces that its Microlyte™ wound dressing technology has won the first annual 2016 Wound Care Innovation Award at the European Wound Management Association (EWMA) conference in Bremen, Germany, held May 11-13, 2106. About 6,000 professionals from wound care industry attended more than 1000 scientific presentations during the three-day conference. More than 180 companies exhibited their newest products.
“We are honored and very pleased that Imbed Biosciences is the first recipient of this prestigious award. Many thanks to the judges who had a very difficult position to choose from the finalists.”
Imbed was one of the five finalists invited to present at the Wound Care Innovation Symposium for the grand prize, sponsored by CMC Consulting Group, EWMA and Lohmann & Rauscher. Each company made a 10 minutes presentation of their technological innovations before an esteemed panel of judges from the industry. The other finalist companies were Kerecis Ltd (Iceland), Birken AG (Germany), Inotec AMD Ltd (UK), and NuTech Medical (AL, USA).
Dr. Mitchell Sanders, Managing Director of Drug and Device Discovery Lab (3DL) at CMC Consulting Group in Boston, MA and host of the symposium, stated: “We are honored and very pleased that Imbed Biosciences is the first recipient of this prestigious award. Many thanks to the judges who had a very difficult position to choose from the finalists.”
Microlyte™ Ag wound dressing is an ultrathin polymeric film with metallic silver coating that absorbs wound fluid, forms a soft gel, and intimately conforms to the underlying wound surface to maintain a moist healing environment. Key benefit of Microlyte™ Ag is that it kills 99.99% of bacteria on its surface for several days while using up to 100 times less silver than competitive dressings. It reduces the risk of silver toxicity and staining, making it safe for use at the onset of any wound management plan, including burns, donor sites, diabetic ulcers and pressure sores. The device is in review at the FDA and has not been cleared for human clinical use.
“We are grateful to receive this recognition and will carry it responsibly by committing to bring this innovative technology to clinicians, hopefully this year,” said Dr. Ankit Agarwal, CEO of Imbed.
Additionally, Imbed will showcase its Microlyte™ film technology at the upcoming Biotechnology Industry Organization (BIO) International Convention in San Francisco, CA, June 6-9, 2016. National Institutes of Health (NIH) has selected Imbed as one of its 50 most promising small business funded technologies to exhibit at the convention. Imbed will host a kiosk in the Innovation Zone on the exhibition floor. About 15,000 biotech leaders from 65 countries are expected to attend the convention. Dr. Agarwal will present the company’s technology and pipeline in a featured track of Company Presentations. He noted, “We would like to thank NIH for getting Imbed this premier visibility at the BIO International Convention. Our team is looking forward to meet licensing partners and investors from around the globe”.
About Imbed Biosciences Inc.
Imbed Biosciences is a privately held medical device company, located in Madison, WI. It is developing next-generation medical devices that can reduce patient pain and costs for the management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its patent-pending synthetic ultrathin polymeric films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Research efforts at Imbed are in part funded by grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com.
Contacts
Imbed Biosciences Inc.
Ankit Agarwal, CEO
ankit@imbedbio.com
